Market research
ONCT Oncternal Therapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 2M
- P/E ratio
- Not available
- Analyst target
- 2
- Dividend yield
- Not available
- Beta
- 1.33
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US68236P1075
- Market cap
- 2M
- P/E ratio
- Not available
- Analyst target
- 2
- Dividend yield
- Not available
- Beta
- 1.33
About
About Oncternal Therapeutics Inc
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ONCT discussion.
5 years, 4 months ago
Oncternal Therapeutics, Inc is currently in a long term downtrend where the price is trading 13.0% below its 200 day moving average.
From a valuation standpoint, the stock is 96.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 49.6.
Oncternal Therapeutics, Inc's total revenue rose by 115.8% to $2M since the same quarter in the previous year.
Its net income has increased by 38.5% to $-3M since the same quarter in the previous year.
Finally, its free cash flow fell by 28.4% to $-4M since the same quarter in the previous year.
Based on the above factors, Oncternal Therapeutics, Inc gets an overall score of 3/5.